Cover Image
市場調查報告書

視網膜靜脈阻塞症:開發中產品分析

Retinal Vein Occlusion - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192808
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
視網膜靜脈阻塞症:開發中產品分析 Retinal Vein Occlusion - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 76 Pages
簡介

所謂視網膜靜脈阻塞症是視網膜靜脈阻塞造成血液流通不暢的疾病。網膜是將影像轉變為神經訊號的組織。主要的症狀有無痛性,突然的視力變化。致病危險因子有動脈粥狀硬化性心血管疾病、黃斑部水腫、糖尿病、高血壓、高膽固醇、年齡等。

本報告提供視網膜靜脈阻塞症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

視網膜靜脈阻塞症概要

治療藥的開發

  • 開發中產品的概要

視網膜靜脈阻塞症:企業開發中的治療藥

視網膜靜脈阻塞症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

視網膜靜脈阻塞症:企業開發中的產品

視網膜靜脈阻塞症的治療藥開發企業

  • Aerpio Therapeutics, Inc.
  • Avalanche Biotechnologies, Inc.
  • EyeGate Pharmaceuticals, Inc.
  • Kala Pharmaceuticals, Inc.
  • Mabion SA
  • NicOx S.A.
  • Ohr Pharmaceutical Inc.
  • Precision Ocular Ltd
  • pSivida Corp.
  • ThromboGenics NV

視網膜靜脈阻塞症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

視網膜靜脈阻塞症:最近的開發平台趨勢

視網膜靜脈阻塞症:暫停中的計劃

視網膜靜脈阻塞症:開發中止的產品

視網膜靜脈阻塞症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8634IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2016, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 7 and 1 respectively.Retinal Vein Occlusion.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinal Vein Occlusion Overview
  • Therapeutics Development
    • Pipeline Products for Retinal Vein Occlusion - Overview
  • Retinal Vein Occlusion - Therapeutics under Development by Companies
  • Retinal Vein Occlusion - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Retinal Vein Occlusion - Products under Development by Companies
  • Retinal Vein Occlusion - Companies Involved in Therapeutics Development
    • Aerpio Therapeutics, Inc.
    • Clearside BioMedical, Inc.
    • Formycon AG
    • Kala Pharmaceuticals, Inc.
    • Mabion SA
    • NicOx S.A.
    • Ohr Pharmaceutical Inc.
    • Precision Ocular Ltd
    • ThromboGenics NV
  • Retinal Vein Occlusion - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (aflibercept + triamcinolone acetonide) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AKB-9778 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HO-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LKA-651 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • loteprednol etabonate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-422 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-434 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ocriplasmin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Ophthalmology and Orphan Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • squalamine lactate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Retinal Vein Occlusion - Dormant Projects
  • Retinal Vein Occlusion - Discontinued Products
  • Retinal Vein Occlusion - Product Development Milestones
    • Featured News & Press Releases
      • Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting
      • Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion
      • Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion
      • Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration
      • Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion
      • Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion
      • Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
      • Jul 31, 2014: Kala Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlusion and Diabetic Macular Edema
      • Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Retinal Vein Occlusion, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Retinal Vein Occlusion - Pipeline by Aerpio Therapeutics, Inc., H2 2016
  • Retinal Vein Occlusion - Pipeline by Clearside BioMedical, Inc., H2 2016
  • Retinal Vein Occlusion - Pipeline by Formycon AG, H2 2016
  • Retinal Vein Occlusion - Pipeline by Kala Pharmaceuticals, Inc., H2 2016
  • Retinal Vein Occlusion - Pipeline by Mabion SA, H2 2016
  • Retinal Vein Occlusion - Pipeline by NicOx S.A., H2 2016
  • Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc., H2 2016
  • Retinal Vein Occlusion - Pipeline by Precision Ocular Ltd, H2 2016
  • Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Retinal Vein Occlusion - Dormant Projects, H2 2016
  • Retinal Vein Occlusion - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Retinal Vein Occlusion, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top